Physician profile
Lawrence Schieken
NPI 1780734871
$12,919.08
in general payments reported to CMS, 2019-2025
22 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,251 · 2021: $484 · 2023: $209 · 2024: $484 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,427.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $594.98 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $424.56 | 2019-2024 | Fasenra |
| Genentech USA, INC. | $226.21 | 2020-2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $213.14 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $174.61 | 2020-2025 | Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $157.50 | 2019-2025 | |
| Blueprint Medicines Corporation | $134.95 | 2023 | Ayvakit |
| Kaleo, INC. | $99.39 | 2019-2021 | |
| Optinose US, INC. | $85.18 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $73.36 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $61.99 | 2021-2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $38.25 | 2020 | |
| Genzyme Corporation | $33.62 | 2019-2021 | |
| Leo Pharma INC. | $29.72 | 2023 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $27.97 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $25.08 | 2021 | |
| Greer Laboratories, INC. | $21.80 | 2019 | |
| Alk-Abello, INC | $20.16 | 2023 | Odactra, Grastek, Ragwitek |
| Shire North American Group INC | $19.92 | 2019 | |
| Amgen INC. | $16.98 | 2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Schieken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.